{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:01:38Z","timestamp":1780516898756,"version":"3.54.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100016468","name":"IRB","doi-asserted-by":"publisher","award":["#66389"],"award-info":[{"award-number":["#66389"]}],"id":[{"id":"10.13039\/100016468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>While there are risk stratification tools for alcohol withdrawal syndrome (AWS), there are no well-established risk factors associated with phenobarbital escalation; the primary aim was to identify risk factors associated with needing phenobarbital dose escalation for AWS management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective, cohort study evaluated adult patients with diagnosed AUD admitted to a surgical or medical intensive care unit of a large academic medical center within 24\u00a0hours of the initial phenobarbital dose for AWS management if admitted between 1 December 2021 and 1 December 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 169 patients, 54 (32.0%) required dose escalation. The univariable analysis demonstrated that patients in the dose escalation group had a significantly higher percentage of preceding Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised scores (CIWA-Ar) scores \u226515, required more concomitant continuous infusion sedation, higher body mass indexes, and shorter times between phenobarbital administration and detectable blood alcohol levels, mechanical ventilation, and hospital admission. In a final multivariable logistic regression model, CIWA-Ar score\u2009\u2265\u200915 (OR: 2.41, (95% CI: 1.25\u20134.69; P\u00a0=\u20090.008) was the only variable helping predict phenobarbital dose escalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on our analysis, elevated CIWA-Ar scores may be the best predictor of phenobarbital dose escalation to treat severe AWS in the critically ill. These findings reinforce the importance of early intervention and dynamic clinical reassessment of phenobarbital dosing in the management of patients with AWS. Further prospective clinical trials are needed to assess risk factors in patients that require escalated treatment for AWS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/alcalc\/agag040","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:10:09Z","timestamp":1778674209000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of risk factors associated with phenobarbital dose escalation for the treatment of alcohol withdrawal in the critically ill"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5889-1032","authenticated-orcid":false,"given":"Madison","family":"Puryear","sequence":"first","affiliation":[{"name":"The Ohio State University Wexner Medical Center , 410 W. 10th St Columbus, OH 43210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Smith","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center , 410 W. 10th St Columbus, OH 43210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Doepker","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center , 410 W. 10th St Columbus, OH 43210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kasick","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center , 410 W. 10th St Columbus, OH 43210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demond","family":"Handley","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center , 410 W. 10th St Columbus, OH 43210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BrookeAnne","family":"Magrum","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center , 410 W. 10th St Columbus, OH 43210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026060315114341200_ref1","volume-title":"SAMHSA, Center for Behavioral Health Statistics and Quality","author":"2022 National Survey on Drug Use and Health","year":"2024"},{"key":"2026060315114341200_ref2","volume-title":"National Center for Drug Abuse Statistics","author":"Alcohol Abuse Statistics","year":"2022"},{"key":"2026060315114341200_ref3","volume-title":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","author":"Alcohol Use Disorder (AUD) in the United States","year":"2024"},{"key":"2026060315114341200_ref4","doi-asserted-by":"publisher","DOI":"10.1097\/ADM","volume":"14","author":"Alvanzo","journal-title":"J Addict Med."},{"key":"2026060315114341200_ref5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/1060028020949137","article-title":"Phenobarbital monotherapy for the management of alcohol withdrawal syndrome in surgical-trauma patients","volume":"55","author":"Ammar","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2026060315114341200_ref6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.drugalcdep.2018.08.017","article-title":"Predictors of resistant alcohol withdrawal (RAW): a retrospective case-control study","volume":"192","author":"Benedict","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2026060315114341200_ref7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/phar.1770","article-title":"Management of acute alcohol withdrawal syndrome in critically ill patients","volume":"36","author":"Dixit","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2026060315114341200_ref8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/01.CCM.0000256841.28351.80","article-title":"A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens","volume":"35","author":"Gold","year":"2007","journal-title":"Crit Care Med"},{"key":"2026060315114341200_ref9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026060315114341200_ref10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00007611-199101000-00006","article-title":"Pharmacokinetic dosing of phenobarbital in the treatment of alcohol withdrawal syndrome","volume":"84","author":"Ives","year":"1991","journal-title":"South Med J"},{"key":"2026060315114341200_ref11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1177\/10600280231221241","article-title":"Phenobarbital versus benzodiazepines for the treatment of severe alcohol withdrawal","volume":"58","author":"Kessel","year":"2024","journal-title":"Ann Pharmacother"},{"key":"2026060315114341200_ref12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/alcalc\/agv043","article-title":"Prospective validation study of the prediction of alcohol withdrawal severity scale (PAWSS) in medically ill inpatients: a new scale for the prediction of complicated alcohol withdrawal syndrome","volume":"50","author":"Maldonado","year":"2015","journal-title":"Alcohol Alcohol"},{"key":"2026060315114341200_ref13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.psym.2016.02.011","article-title":"The role of barbiturates for alcohol withdrawal syndrome","volume":"57","author":"Martin","year":"2016","journal-title":"Psychosomatics"},{"key":"2026060315114341200_ref14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00228-020-03011-x","article-title":"Pharmacokinetic variability of phenobarbital: a systematic review of population pharmacokinetic analysis","volume":"77","author":"Methaneethorn","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2026060315114341200_ops-bib-reference-tmplbfqj7ao9un16","doi-asserted-by":"publisher","volume-title":"Annals of Pharmacotherapy","DOI":"10.1345\/aph.19381"},{"key":"2026060315114341200_ref15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s13181-022-00900-8","article-title":"Front-loaded versus low-intermittent phenobarbital dosing for benzodiazepine-resistant severe alcohol withdrawal syndrome","volume":"18","author":"Shah","year":"2022","journal-title":"J Med Toxicol"},{"key":"2026060315114341200_ref16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.genhosppsych.2023.10.014","article-title":"Evaluation of phenobarbital dosing strategies for hospitalized patients with alcohol withdrawal syndrome","volume":"85","author":"Stallworth","year":"2023","journal-title":"Gen Hosp Psychiatry"},{"key":"2026060315114341200_ref17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4037\/ajcc2018745","article-title":"Treatment of alcohol withdrawal syndrome: phenobarbital vs CIWA-Ar protocol","volume":"27","author":"Tidwell","year":"2018","journal-title":"Am J Crit Care"},{"key":"2026060315114341200_ref18","doi-asserted-by":"publisher","first-page":"e33695","DOI":"10.7759\/cureus.33695","article-title":"Phenobarbital and alcohol withdrawal syndrome: a systematic review and meta-analysis","volume":"15","author":"Umar","year":"2023","journal-title":"Cureus"},{"key":"2026060315114341200_ref19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.drugalcdep.2015.07.005","article-title":"Management of benzodiazepine-resistant alcohol withdrawal across a healthcare system: benzodiazepine dose-escalation with or without propofol","volume":"154","author":"Wong","year":"2015","journal-title":"Drug Alcohol Depend"}],"container-title":["Alcohol and Alcoholism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/61\/4\/agag040\/68463554\/agag040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/61\/4\/agag040\/68463554\/agag040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:11:51Z","timestamp":1780513911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/alcalc\/article\/doi\/10.1093\/alcalc\/agag040\/8700940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5,13]]}},"URL":"https:\/\/doi.org\/10.1093\/alcalc\/agag040","relation":{},"ISSN":["0735-0414","1464-3502"],"issn-type":[{"value":"0735-0414","type":"print"},{"value":"1464-3502","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,13]]},"article-number":"agag040"}}